Cytoplasmic Autoantibodies in the Anti-Synthetase Syndrome

Save

Patients known to be autoantibody positive (e.g., anti- Jo1) for the anti-synthetase syndrome were assayed by indirect immunofluorescence (IIF) for other reactivities, showing antinuclear staining (ANA) or cytoplasmic staining (Anti-Cyt Ab+).

The RheumNow Week in Review – 20 January 2017

Save

Dr. Jack Cush reviews highlights from the past week on RheumNow.

Consensus Guidelines for Juvenile Dermatomyositis Management

Save

SHARE (Single Hub and Access point for pediatric Rheumatology in Europe) was established in 2012 to optimise the diagnosis and treatment of several pediatric diseases. They have recently published their recommendations regarding the diagnosis and management of juvenile dermatomyositis (JDM).

Statins Don't Increase Risk of Colchicine Myopathy

Save

Neuromyopathy is a rare side effect of chronic colchicine use. Statins are more commonly implicated as a cause of drug-induced myopathy.  

Given the frequent occurrence of the metabolic syndrome, simultaneous use of both colchicine and statins is common.

Necrotizing Myopathy is a Unique Form of Myositis

Save

Muscle involvement in immune-mediated necrotizing myopathy (IMNM) was more extensive compared with other inflammatory myopathies, according to a retrospective chart review.

HMGB1 as a Biomarker for Polymyositis and Dermatomyositis

Save

High mobility group box chromosomal protein 1 (HMGB1) is a DNA-binding protein that functions as a structural co-factor. HMGB1 is actively secreted by macrophage/monocytes via inflammatory stimuli and is elaborated during apoptosis.

RheumNow Week in Review – 12 August 2016

Save

Watch Dr. Cush review 13 highlights from this week on RheumNow.

Consensus Recommendations for Juvenile Dermatomyositis

Save

SHARE (Single Hub and Access point for pediatric Rheumatology in Europe) is a group established in 2012 to develop and optimize diagnostic and management regimens in Europe for children and young adults with rheumatic diseases.

April-May 2016 Top Social Media News

Save

In April and May 2016, RheumNow sent 82 tweets regarding news, research and teaching points that strongly impacted the rheumatology community and resulted in a reach of 203,500 impressions, with 136 mentions, and over 6378 visits to RheumNow.com. Here are the top tweets from April and May.

RheumNow Week in Review - 3 June 2016

Save

This week's highlights from RheumNow.com include:

Poor Outcomes for Dermato/Polymyositis Admitted to ICU

Save

Idiopathic inflammatory myopathies (IIMs) may be complicated with life-threatening conditions requiring intensive care unit (ICU) admission.  The outcomes of such complications may be dire, but there are few series addressing the outcomes of those admitted to the ICU. 

Drug Safety Bulletin - March 2016

Save

RheumNow is committed to reporting safety issues in our monthly Drug Safety Bulletins, wherein we will update you with reports of new, ongoing and resolved Drug Shortages that will affect rheumatology.   If you have suggestions or information about specific drug sho

Statin-Induced Autoimmune Myopathy

Save

The CDC estimates nearly 71% of adults with cardiovascular disease and 54% of adults with hypercholesterolemia use a cholesterol-lowering

Challenges of Dermatomyositis Progress

Save

In the current issue of Lancet, Pierre Miossec discusses the challenges of studying and managing juvenile dermatomyositis and, specifically, the

Features Predict Chronicity in Myositis

Save

Certain serologic and clinical features can help predict a chronic disease course among children with juvenile idiopathic inflammatory myopathies (JIIM), a large registry study showed.

Antibody Predicts Lung Disease in Myositis

Save

Patients in the U.S. with myositis who are positive for the anti-MDA5 autoantibody are at high risk for developing interstitial lung disease (ILD), a retrospective study found.